Abstract
Aim: To explore the anti-inflammatory effects of a novel peptide designed to bind with the NF-κB p50 subunit. Methods: The affinity of the peptide binding with p50 was measured with a biosensor. Levels of tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) from a human acute monocytic leukemia cell line (THP-1) treated with lipopolysaccharide (LPS) were measured using the ELISA method. In vivo anti-inflammatory effects of the peptide were tested with phorbol myristate acetate (PMA)-induced ear edema and zymosan A-induced peritonitis in mice. Results: The peptide has the ability to interact with the NF-κB p50 subunit and can effectively inhibit TNF-α and IL-6 production in the THP-1 cell line, PMA-induced ear edema and zymosan A-induced peritonitis in mice. Conclusion: The peptide may have therapeutic potential for the treatment of local acute inflammation. © 2006 CPS and SIMM.
Author supplied keywords
Cite
CITATION STYLE
Wang, Z. P., Cai, S. X., Liu, D. B., Xu, X., & Liang, H. P. (2006). Anti-inflammatory effects of a novel peptide designed to bind with NF-κB p50 subunit. Acta Pharmacologica Sinica, 27(11), 1474–1478. https://doi.org/10.1111/j.1745-7254.2006.00442.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.